Loading…

Benefit of exercise therapy for systolic heart failure in relation to disease severity and etiology—findings from the Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training study

Background This post hoc analysis of the HF-ACTION cohort explores the primary and secondary results of the HF-ACTION study by etiology and severity of illness. Methods HF-ACTION randomized stable outpatients with reduced left ventricular (LV) function and heart failure (HF) symptoms to either super...

Full description

Saved in:
Bibliographic Details
Published in:The American heart journal 2011-12, Vol.162 (6), p.1003-1010
Main Authors: Whellan, David J., MD, MHS, Nigam, Anil, MD, Arnold, Malcolm, MD, Starr, Aijing Z., MS, Hill, James, MD, MS, Fletcher, Gerald, MD, Ellis, Stephen J., PhD, Cooper, Lawton, MD, Onwuanyi, Anekwe, MD, Chandler, Bleakley, MD, Keteyian, Steven J., PhD, Ewald, Greg, MD, Kao, Andrew, MD, Gheorghiade, Mihai, MD
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c607t-fd98f830dcf93d8d3cbf4f131bb778175a858e3a2da2f8233f26d876cfb861e53
cites cdi_FETCH-LOGICAL-c607t-fd98f830dcf93d8d3cbf4f131bb778175a858e3a2da2f8233f26d876cfb861e53
container_end_page 1010
container_issue 6
container_start_page 1003
container_title The American heart journal
container_volume 162
creator Whellan, David J., MD, MHS
Nigam, Anil, MD
Arnold, Malcolm, MD
Starr, Aijing Z., MS
Hill, James, MD, MS
Fletcher, Gerald, MD
Ellis, Stephen J., PhD
Cooper, Lawton, MD
Onwuanyi, Anekwe, MD
Chandler, Bleakley, MD
Keteyian, Steven J., PhD
Ewald, Greg, MD
Kao, Andrew, MD
Gheorghiade, Mihai, MD
description Background This post hoc analysis of the HF-ACTION cohort explores the primary and secondary results of the HF-ACTION study by etiology and severity of illness. Methods HF-ACTION randomized stable outpatients with reduced left ventricular (LV) function and heart failure (HF) symptoms to either supervised exercise training plus usual care or to usual care alone. The primary outcome was all-cause mortality or all-cause hospitalization; secondary outcomes included all-cause mortality, cardiovascular mortality or cardiovascular hospitalization, and cardiovascular mortality or HF hospitalization. The interaction between treatment and risk variable, etiology or severity as determined by risk score, New York Heart Association class, and duration of cardiopulmonary exercise test was examined in a Cox proportional hazards model for all clinical end points. Results There was no interaction between etiology and treatment for the primary outcome ( P = .73), cardiovascular (CV) mortality or CV hospitalization ( P = .59), or CV mortality or HF hospitalization ( P = .07). There was a significant interaction between etiology and treatment for the outcome of mortality ( P = .03), but the interaction was no longer significant when adjusted for HF-ACTION adjustment model predictors ( P = .08). There was no significant interaction between treatment effect and severity, except a significant interaction between cardiopulmonary exercise duration and training was identified for the primary outcome of all-cause mortality or all-cause hospitalization. Conclusion Consideration of symptomatic (New York Heart Association classes II to IV) patients with HF with reduced LV function for participation in an exercise training program should be made independent of the cause of HF or the severity of the symptoms.
doi_str_mv 10.1016/j.ahj.2011.09.017
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_908739669</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0002870311007022</els_id><sourcerecordid>908739669</sourcerecordid><originalsourceid>FETCH-LOGICAL-c607t-fd98f830dcf93d8d3cbf4f131bb778175a858e3a2da2f8233f26d876cfb861e53</originalsourceid><addsrcrecordid>eNp9ks1uEzEUhUcIREPhAdggSwjBJsE_ydgjJKQStbRSpS4Ia8uxrxOHiR1sT8TseAiei4fgSfCQlEpddGVZ_s65Pz5V9ZLgCcGkfr-ZqPVmQjEhE9xMMOGPqhHBDR_XfDp9XI0wxnQsOGYn1bOUNuVaU1E_rU4oJYxjzkbV70_gwbqMgkXwA6J2CVBeQ1S7HtkQUepTDq3TaA0qZmSVa7sIyHkUoVXZBY9yQKbIVFEm2EN0uUfKGwTltQ2r_s_PX9Z54_wqIRvDdvBHl__sLo52A36G5sHnGNoWDFpEp1p05feQsluVOn6FbrqswxbS0Ov5ba-LqJwfXlPuTP-8emJVm-DF8Tytvl6cL-aX4-ubz1fzs-uxrjHPY2saYQXDRtuGGWGYXtqpJYwsl5wLwmdKzAQwRY2iVlDGLK2N4LW2S1ETmLHT6u3BdxfD9670KLcuaWhb5SF0STZYcNbUdVPIdw-SZMamgoipGExf30M3oYu-zFEoQmssGjoYkgOlY0gpgpW76LYq9pJgOcRCbmSJhRxiIXEjSyyK5tXRuVtuwfxX3OagAG-OgEpatTYqX7Z7x80YnhFBCvfhwEFZ7t5BlEk78BqMi6CzNME92MbHe2rdls8rBb9BD-luWpmoxPLLkN8hvoRgzDGl7C-5u-6t</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1512608929</pqid></control><display><type>article</type><title>Benefit of exercise therapy for systolic heart failure in relation to disease severity and etiology—findings from the Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training study</title><source>Elsevier</source><creator>Whellan, David J., MD, MHS ; Nigam, Anil, MD ; Arnold, Malcolm, MD ; Starr, Aijing Z., MS ; Hill, James, MD, MS ; Fletcher, Gerald, MD ; Ellis, Stephen J., PhD ; Cooper, Lawton, MD ; Onwuanyi, Anekwe, MD ; Chandler, Bleakley, MD ; Keteyian, Steven J., PhD ; Ewald, Greg, MD ; Kao, Andrew, MD ; Gheorghiade, Mihai, MD</creator><creatorcontrib>Whellan, David J., MD, MHS ; Nigam, Anil, MD ; Arnold, Malcolm, MD ; Starr, Aijing Z., MS ; Hill, James, MD, MS ; Fletcher, Gerald, MD ; Ellis, Stephen J., PhD ; Cooper, Lawton, MD ; Onwuanyi, Anekwe, MD ; Chandler, Bleakley, MD ; Keteyian, Steven J., PhD ; Ewald, Greg, MD ; Kao, Andrew, MD ; Gheorghiade, Mihai, MD</creatorcontrib><description>Background This post hoc analysis of the HF-ACTION cohort explores the primary and secondary results of the HF-ACTION study by etiology and severity of illness. Methods HF-ACTION randomized stable outpatients with reduced left ventricular (LV) function and heart failure (HF) symptoms to either supervised exercise training plus usual care or to usual care alone. The primary outcome was all-cause mortality or all-cause hospitalization; secondary outcomes included all-cause mortality, cardiovascular mortality or cardiovascular hospitalization, and cardiovascular mortality or HF hospitalization. The interaction between treatment and risk variable, etiology or severity as determined by risk score, New York Heart Association class, and duration of cardiopulmonary exercise test was examined in a Cox proportional hazards model for all clinical end points. Results There was no interaction between etiology and treatment for the primary outcome ( P = .73), cardiovascular (CV) mortality or CV hospitalization ( P = .59), or CV mortality or HF hospitalization ( P = .07). There was a significant interaction between etiology and treatment for the outcome of mortality ( P = .03), but the interaction was no longer significant when adjusted for HF-ACTION adjustment model predictors ( P = .08). There was no significant interaction between treatment effect and severity, except a significant interaction between cardiopulmonary exercise duration and training was identified for the primary outcome of all-cause mortality or all-cause hospitalization. Conclusion Consideration of symptomatic (New York Heart Association classes II to IV) patients with HF with reduced LV function for participation in an exercise training program should be made independent of the cause of HF or the severity of the symptoms.</description><identifier>ISSN: 0002-8703</identifier><identifier>EISSN: 1097-6744</identifier><identifier>DOI: 10.1016/j.ahj.2011.09.017</identifier><identifier>PMID: 22137073</identifier><identifier>CODEN: AHJOA2</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Aged ; Biological and medical sciences ; Cardiology. Vascular system ; Cardiomyopathy ; Cardiovascular ; Cardiovascular disease ; Clinical trials ; Exercise Therapy ; Female ; Heart ; Heart attacks ; Heart failure ; Heart failure, cardiogenic pulmonary edema, cardiac enlargement ; Heart Failure, Systolic - etiology ; Heart Failure, Systolic - therapy ; Hospitalization ; Humans ; Illnesses ; Male ; Medical sciences ; Middle Aged ; Mortality ; Older people ; Patients ; Severity of Illness Index ; Treatment Outcome ; Ventricular Dysfunction, Left</subject><ispartof>The American heart journal, 2011-12, Vol.162 (6), p.1003-1010</ispartof><rights>Mosby, Inc.</rights><rights>2011 Mosby, Inc.</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2011 Mosby, Inc. All rights reserved.</rights><rights>Copyright Elsevier Limited Dec 2011</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c607t-fd98f830dcf93d8d3cbf4f131bb778175a858e3a2da2f8233f26d876cfb861e53</citedby><cites>FETCH-LOGICAL-c607t-fd98f830dcf93d8d3cbf4f131bb778175a858e3a2da2f8233f26d876cfb861e53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=25305181$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22137073$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Whellan, David J., MD, MHS</creatorcontrib><creatorcontrib>Nigam, Anil, MD</creatorcontrib><creatorcontrib>Arnold, Malcolm, MD</creatorcontrib><creatorcontrib>Starr, Aijing Z., MS</creatorcontrib><creatorcontrib>Hill, James, MD, MS</creatorcontrib><creatorcontrib>Fletcher, Gerald, MD</creatorcontrib><creatorcontrib>Ellis, Stephen J., PhD</creatorcontrib><creatorcontrib>Cooper, Lawton, MD</creatorcontrib><creatorcontrib>Onwuanyi, Anekwe, MD</creatorcontrib><creatorcontrib>Chandler, Bleakley, MD</creatorcontrib><creatorcontrib>Keteyian, Steven J., PhD</creatorcontrib><creatorcontrib>Ewald, Greg, MD</creatorcontrib><creatorcontrib>Kao, Andrew, MD</creatorcontrib><creatorcontrib>Gheorghiade, Mihai, MD</creatorcontrib><title>Benefit of exercise therapy for systolic heart failure in relation to disease severity and etiology—findings from the Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training study</title><title>The American heart journal</title><addtitle>Am Heart J</addtitle><description>Background This post hoc analysis of the HF-ACTION cohort explores the primary and secondary results of the HF-ACTION study by etiology and severity of illness. Methods HF-ACTION randomized stable outpatients with reduced left ventricular (LV) function and heart failure (HF) symptoms to either supervised exercise training plus usual care or to usual care alone. The primary outcome was all-cause mortality or all-cause hospitalization; secondary outcomes included all-cause mortality, cardiovascular mortality or cardiovascular hospitalization, and cardiovascular mortality or HF hospitalization. The interaction between treatment and risk variable, etiology or severity as determined by risk score, New York Heart Association class, and duration of cardiopulmonary exercise test was examined in a Cox proportional hazards model for all clinical end points. Results There was no interaction between etiology and treatment for the primary outcome ( P = .73), cardiovascular (CV) mortality or CV hospitalization ( P = .59), or CV mortality or HF hospitalization ( P = .07). There was a significant interaction between etiology and treatment for the outcome of mortality ( P = .03), but the interaction was no longer significant when adjusted for HF-ACTION adjustment model predictors ( P = .08). There was no significant interaction between treatment effect and severity, except a significant interaction between cardiopulmonary exercise duration and training was identified for the primary outcome of all-cause mortality or all-cause hospitalization. Conclusion Consideration of symptomatic (New York Heart Association classes II to IV) patients with HF with reduced LV function for participation in an exercise training program should be made independent of the cause of HF or the severity of the symptoms.</description><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Cardiology. Vascular system</subject><subject>Cardiomyopathy</subject><subject>Cardiovascular</subject><subject>Cardiovascular disease</subject><subject>Clinical trials</subject><subject>Exercise Therapy</subject><subject>Female</subject><subject>Heart</subject><subject>Heart attacks</subject><subject>Heart failure</subject><subject>Heart failure, cardiogenic pulmonary edema, cardiac enlargement</subject><subject>Heart Failure, Systolic - etiology</subject><subject>Heart Failure, Systolic - therapy</subject><subject>Hospitalization</subject><subject>Humans</subject><subject>Illnesses</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Older people</subject><subject>Patients</subject><subject>Severity of Illness Index</subject><subject>Treatment Outcome</subject><subject>Ventricular Dysfunction, Left</subject><issn>0002-8703</issn><issn>1097-6744</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><recordid>eNp9ks1uEzEUhUcIREPhAdggSwjBJsE_ydgjJKQStbRSpS4Ia8uxrxOHiR1sT8TseAiei4fgSfCQlEpddGVZ_s65Pz5V9ZLgCcGkfr-ZqPVmQjEhE9xMMOGPqhHBDR_XfDp9XI0wxnQsOGYn1bOUNuVaU1E_rU4oJYxjzkbV70_gwbqMgkXwA6J2CVBeQ1S7HtkQUepTDq3TaA0qZmSVa7sIyHkUoVXZBY9yQKbIVFEm2EN0uUfKGwTltQ2r_s_PX9Z54_wqIRvDdvBHl__sLo52A36G5sHnGNoWDFpEp1p05feQsluVOn6FbrqswxbS0Ov5ba-LqJwfXlPuTP-8emJVm-DF8Tytvl6cL-aX4-ubz1fzs-uxrjHPY2saYQXDRtuGGWGYXtqpJYwsl5wLwmdKzAQwRY2iVlDGLK2N4LW2S1ETmLHT6u3BdxfD9670KLcuaWhb5SF0STZYcNbUdVPIdw-SZMamgoipGExf30M3oYu-zFEoQmssGjoYkgOlY0gpgpW76LYq9pJgOcRCbmSJhRxiIXEjSyyK5tXRuVtuwfxX3OagAG-OgEpatTYqX7Z7x80YnhFBCvfhwEFZ7t5BlEk78BqMi6CzNME92MbHe2rdls8rBb9BD-luWpmoxPLLkN8hvoRgzDGl7C-5u-6t</recordid><startdate>20111201</startdate><enddate>20111201</enddate><creator>Whellan, David J., MD, MHS</creator><creator>Nigam, Anil, MD</creator><creator>Arnold, Malcolm, MD</creator><creator>Starr, Aijing Z., MS</creator><creator>Hill, James, MD, MS</creator><creator>Fletcher, Gerald, MD</creator><creator>Ellis, Stephen J., PhD</creator><creator>Cooper, Lawton, MD</creator><creator>Onwuanyi, Anekwe, MD</creator><creator>Chandler, Bleakley, MD</creator><creator>Keteyian, Steven J., PhD</creator><creator>Ewald, Greg, MD</creator><creator>Kao, Andrew, MD</creator><creator>Gheorghiade, Mihai, MD</creator><general>Elsevier Inc</general><general>Mosby</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7RV</scope><scope>7TS</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20111201</creationdate><title>Benefit of exercise therapy for systolic heart failure in relation to disease severity and etiology—findings from the Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training study</title><author>Whellan, David J., MD, MHS ; Nigam, Anil, MD ; Arnold, Malcolm, MD ; Starr, Aijing Z., MS ; Hill, James, MD, MS ; Fletcher, Gerald, MD ; Ellis, Stephen J., PhD ; Cooper, Lawton, MD ; Onwuanyi, Anekwe, MD ; Chandler, Bleakley, MD ; Keteyian, Steven J., PhD ; Ewald, Greg, MD ; Kao, Andrew, MD ; Gheorghiade, Mihai, MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c607t-fd98f830dcf93d8d3cbf4f131bb778175a858e3a2da2f8233f26d876cfb861e53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Cardiology. Vascular system</topic><topic>Cardiomyopathy</topic><topic>Cardiovascular</topic><topic>Cardiovascular disease</topic><topic>Clinical trials</topic><topic>Exercise Therapy</topic><topic>Female</topic><topic>Heart</topic><topic>Heart attacks</topic><topic>Heart failure</topic><topic>Heart failure, cardiogenic pulmonary edema, cardiac enlargement</topic><topic>Heart Failure, Systolic - etiology</topic><topic>Heart Failure, Systolic - therapy</topic><topic>Hospitalization</topic><topic>Humans</topic><topic>Illnesses</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Older people</topic><topic>Patients</topic><topic>Severity of Illness Index</topic><topic>Treatment Outcome</topic><topic>Ventricular Dysfunction, Left</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Whellan, David J., MD, MHS</creatorcontrib><creatorcontrib>Nigam, Anil, MD</creatorcontrib><creatorcontrib>Arnold, Malcolm, MD</creatorcontrib><creatorcontrib>Starr, Aijing Z., MS</creatorcontrib><creatorcontrib>Hill, James, MD, MS</creatorcontrib><creatorcontrib>Fletcher, Gerald, MD</creatorcontrib><creatorcontrib>Ellis, Stephen J., PhD</creatorcontrib><creatorcontrib>Cooper, Lawton, MD</creatorcontrib><creatorcontrib>Onwuanyi, Anekwe, MD</creatorcontrib><creatorcontrib>Chandler, Bleakley, MD</creatorcontrib><creatorcontrib>Keteyian, Steven J., PhD</creatorcontrib><creatorcontrib>Ewald, Greg, MD</creatorcontrib><creatorcontrib>Kao, Andrew, MD</creatorcontrib><creatorcontrib>Gheorghiade, Mihai, MD</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>ProQuest Nursing &amp; Allied Health Database</collection><collection>Physical Education Index</collection><collection>ProQuest Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>ProQuest Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest research library</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The American heart journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Whellan, David J., MD, MHS</au><au>Nigam, Anil, MD</au><au>Arnold, Malcolm, MD</au><au>Starr, Aijing Z., MS</au><au>Hill, James, MD, MS</au><au>Fletcher, Gerald, MD</au><au>Ellis, Stephen J., PhD</au><au>Cooper, Lawton, MD</au><au>Onwuanyi, Anekwe, MD</au><au>Chandler, Bleakley, MD</au><au>Keteyian, Steven J., PhD</au><au>Ewald, Greg, MD</au><au>Kao, Andrew, MD</au><au>Gheorghiade, Mihai, MD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Benefit of exercise therapy for systolic heart failure in relation to disease severity and etiology—findings from the Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training study</atitle><jtitle>The American heart journal</jtitle><addtitle>Am Heart J</addtitle><date>2011-12-01</date><risdate>2011</risdate><volume>162</volume><issue>6</issue><spage>1003</spage><epage>1010</epage><pages>1003-1010</pages><issn>0002-8703</issn><eissn>1097-6744</eissn><coden>AHJOA2</coden><abstract>Background This post hoc analysis of the HF-ACTION cohort explores the primary and secondary results of the HF-ACTION study by etiology and severity of illness. Methods HF-ACTION randomized stable outpatients with reduced left ventricular (LV) function and heart failure (HF) symptoms to either supervised exercise training plus usual care or to usual care alone. The primary outcome was all-cause mortality or all-cause hospitalization; secondary outcomes included all-cause mortality, cardiovascular mortality or cardiovascular hospitalization, and cardiovascular mortality or HF hospitalization. The interaction between treatment and risk variable, etiology or severity as determined by risk score, New York Heart Association class, and duration of cardiopulmonary exercise test was examined in a Cox proportional hazards model for all clinical end points. Results There was no interaction between etiology and treatment for the primary outcome ( P = .73), cardiovascular (CV) mortality or CV hospitalization ( P = .59), or CV mortality or HF hospitalization ( P = .07). There was a significant interaction between etiology and treatment for the outcome of mortality ( P = .03), but the interaction was no longer significant when adjusted for HF-ACTION adjustment model predictors ( P = .08). There was no significant interaction between treatment effect and severity, except a significant interaction between cardiopulmonary exercise duration and training was identified for the primary outcome of all-cause mortality or all-cause hospitalization. Conclusion Consideration of symptomatic (New York Heart Association classes II to IV) patients with HF with reduced LV function for participation in an exercise training program should be made independent of the cause of HF or the severity of the symptoms.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>22137073</pmid><doi>10.1016/j.ahj.2011.09.017</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0002-8703
ispartof The American heart journal, 2011-12, Vol.162 (6), p.1003-1010
issn 0002-8703
1097-6744
language eng
recordid cdi_proquest_miscellaneous_908739669
source Elsevier
subjects Aged
Biological and medical sciences
Cardiology. Vascular system
Cardiomyopathy
Cardiovascular
Cardiovascular disease
Clinical trials
Exercise Therapy
Female
Heart
Heart attacks
Heart failure
Heart failure, cardiogenic pulmonary edema, cardiac enlargement
Heart Failure, Systolic - etiology
Heart Failure, Systolic - therapy
Hospitalization
Humans
Illnesses
Male
Medical sciences
Middle Aged
Mortality
Older people
Patients
Severity of Illness Index
Treatment Outcome
Ventricular Dysfunction, Left
title Benefit of exercise therapy for systolic heart failure in relation to disease severity and etiology—findings from the Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training study
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T19%3A21%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Benefit%20of%20exercise%20therapy%20for%20systolic%20heart%20failure%20in%20relation%20to%20disease%20severity%20and%20etiology%E2%80%94findings%20from%20the%20Heart%20Failure%20and%20A%20Controlled%20Trial%20Investigating%20Outcomes%20of%20Exercise%20Training%20study&rft.jtitle=The%20American%20heart%20journal&rft.au=Whellan,%20David%20J.,%20MD,%20MHS&rft.date=2011-12-01&rft.volume=162&rft.issue=6&rft.spage=1003&rft.epage=1010&rft.pages=1003-1010&rft.issn=0002-8703&rft.eissn=1097-6744&rft.coden=AHJOA2&rft_id=info:doi/10.1016/j.ahj.2011.09.017&rft_dat=%3Cproquest_cross%3E908739669%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c607t-fd98f830dcf93d8d3cbf4f131bb778175a858e3a2da2f8233f26d876cfb861e53%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1512608929&rft_id=info:pmid/22137073&rfr_iscdi=true